Substance in grapes prevents agglomeration of a mutant protein that leads to cancer

June 27, 2018, Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)
(1) Resveratrol inhibits wild-type and mutant p53C aggregation in vitro. (2) Mutations in p53 protein in cancer cells are directly associated with amyloid aggregation. (3) Resveratrol impairs the formation of p53 amyloid-aggregates in MDA-MB-231 and HCC-70 human breast cancer cells and reduces cell migration and proliferation. (4) However, in the absence of this bioactive compound, massive nuclear accumulation of the aggregates occurs, increasing cancer aggressiveness and progression. Credit: Danielly C. Ferraz da Costa

Researchers at the Federal University of Rio de Janeiro (UFRJ) and the State University of Rio de Janeiro (UERJ) have made a discovery that could lead to the development of a treatment against more than half of breast cancer cases. Using resveratrol, a bioactive compound found in grapes and red wine, scientists were able for the first time to inhibit the agglomeration of mutant versions of the p53 protein, a structure present in about 60 percent of tumors, and to prevent migration and proliferation of breast cancer cells.

The potential anti-cancer effects of have been known for years, but to date, no study has been able to show that the substance can act to reduce tumors caused by the aggregation of the mutant form of . The Brazilian scientists are the first to obtain this result in the laboratory.

Because they are found in more than half of malignant tumors, amyloid aggregates of mutant p53 are considered novel strategic targets in the fight against cancer. In its normal, unmutated version, the protein is responsible for the suppression of cells, and for this reason is often referred to as "guardian of the genome." A mutant p53, however, can lose that function and gain others, sequestering its normal counterparts and contributing to the formation of amyloid aggregates, structures of difficult degradation and rapid growth. Some are extremely pathogenic, while others are harmless.

The laboratory of Professor Jerson Lima Silva has been investigating the amyloid aggregation of p53 for two decades. The main goal of this group is to understand the mechanisms that allow aggregates of mutant p53 to contribute to cancer and to find an effective way to prevent it from forming.

"The findings bring scientists closer to the development of a drug capable of acting directly on the amyloid aggregation of the mutant p53," says Danielly C. Ferraz da Costa, a co-author of the study, from the Institute of Nutrition of UERJ and a member of the INBEB. She began studying the properties of resveratrol for her doctoral thesis, and by 2012 had already investigated the anticancer protection by resveratrol in lung tumor cells.

The researchers applied fluorescence spectroscopy techniques in vitro to test the antitumor potential of resveratrol in aggregations of wild and mutant p53. In addition, they used immunofluorescence co-localization assays to test the action of the substance on breast cancer cells with different p53 mutants (MDA-MB-231 and HCC-70) and normal p53 (MCF-7). Decreased aggregation of mutated p53 was observed in tumors implanted in mice. The group is now studying various molecules derived from resveratrol that can be used in therapy against tumors containing mutated p53.

The paper, titled "Resveratrol prevents p53 in vitro and in ," is published online in Oncotarget.

Explore further: The genome guardian turns to the dark side: Opportunity for drug discovery against cancer?

More information: "Resveratrol prevents p53 aggregation in vitro and in breast cancer cells" Oncotarget (2018). DOI: 10.18632/oncotarget.25631 , http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=25631&path%5B%5D=80217

Journal reference: Oncotarget search and more info website

Provided by: Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)

12 shares

Related Stories

The genome guardian turns to the dark side: Opportunity for drug discovery against cancer?

June 1, 2018
Abnormal changes in the p53 protein are associated with many cancers. In fact, the gene that codes the p53 protein is the one most frequently mutated in human cancers. The protein, known as the guardian of the genome, has ...

Red wine ingredient resveratrol stops breast cancer growth

September 29, 2011
Cheers! A new research report appearing in the October 2011 issue of The FASEB Journal shows that resveratrol, the "healthy" ingredient in red wine, stops breast cancer cells from growing by blocking the growth effects of ...

A sip of resveratrol and a full p53: Ingredients for a successful cell death

November 13, 2012
Researchers at the Universidade Federal in Rio de Janeiro in Brazil have found that introduction of a normal copy of the p53 gene in p53-defective cancer cell lines makes these cells sensitive to the anti-tumor proprieties ...

New findings may improve treatment of inherited breast cancer

October 9, 2008
Scientists have identified some of the elusive downstream molecules that play a critical role in the development and progression of familial breast cancer. The research, published by Cell Press in the October 10th issue of ...

Prions and cancer: A story unfolding

June 25, 2012
Prions, the causal agents of Mad Cow and other diseases, are very unique infectious particles. They are proteins in which the complex molecular three-dimensional folding process just went astray. For reasons not yet understood, ...

Combination breast cancer therapy targets tumor cells and the blood vessels that feed them

March 26, 2018
Each day, normal human cell tissues express a protein known as p53 that wages war against potential malignancies. However, between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53 that helps ...

Recommended for you

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Method identified to reduce risk of brain damage in leukemia survivors

September 25, 2018
Children with acute lymphoblastic leukemia (ALL) are at an extremely high risk of sepsis compared to the general population. In the first-published study of its kind, St. Jude Children's Research Hospital scientists have ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.